Complications of botulinum toxin and dermal fillers
A combined overview of injectable complications organised by time of onset and by agent, with the vascular versus non-vascular split that determines urgency.
Complication lists are usually organised by product. That arrangement is convenient for learning and unhelpful in the room, because the first decision after an injectable complication is not which product caused it but how quickly it must be acted on.
The triage split
Every injectable complication falls on one side of a single line: vascular or non-vascular. Vascular events — arterial occlusion, embolic visual loss, and the tissue ischaemia that follows — are time-critical, and published management guidelines are built around minimising delay. Everything else, including infection, nodules, asymmetry, migration and unsatisfactory aesthetic outcome, matters but is not measured in minutes.
Applying that split first is the entire point of it. It is why pain disproportionate to the procedure, immediate blanching, or any visual symptom is treated as an emergency until proven otherwise, rather than being weighed in a differential list alongside bruising.
By onset
Immediate — during, or minutes after. Vascular occlusion, with pain, blanching, and mottled or dusky discolouration following a defined vascular territory. Visual disturbance, ocular pain, ptosis or ophthalmoplegia, indicating embolic involvement of the orbital circulation. Vasovagal episodes. Immediate hypersensitivity is rare but reported.
Early — hours to days. Evolving ischaemic change, blistering and impending necrosis where an occlusion was missed or incompletely treated. Bruising and oedema. Acute infection. Herpes simplex reactivation. For botulinum toxin, this is the window in which spread beyond the target muscle presents: brow ptosis, eyelid ptosis, an asymmetric smile, or swallowing difficulty after lower-face and neck treatment.
Late — weeks to months and beyond. Delayed-onset nodules, granulomatous reactions, biofilm, product migration, contour irregularity, Tyndall effect from superficially placed hyaluronic acid, and persistent oedema in regions with limited lymphatic drainage.
By agent
Botulinum toxin complications are overwhelmingly functional and self-limiting. The mechanism is diffusion or misplacement, and the effect resolves as the toxin’s action wears off, which makes explanation and time the principal management. That does not make them trivial: eyelid ptosis lasting weeks is a significant event for the patient, and swallowing difficulty after neck injection is a safety matter rather than a cosmetic one.
Fillers carry the mechanical and vascular complications. Hyaluronic acid products have the practical advantage that the material can be enzymatically degraded; non-hyaluronic and particulate products cannot be, which alters the whole management pathway for a misplacement or a delayed nodule.
Contributing factors
Analyses of vascular occlusion series identify contributing factors rather than a single cause: high-risk anatomical regions, previous surgery or previous filler in the area with altered planes and scarring, bolus delivery, injection pressure, and larger volumes deposited at a single point. Prior treatment is easy to under-weight during assessment, and case series repeatedly note it.
What matters more than the list
Recognition and readiness. Consent that names visual loss, a written pathway agreed before it is needed, immediate access to hyaluronidase wherever hyaluronic acid is used, and an identified route to urgent ophthalmology. Complications occur in competent hands. What separates the reported outcomes is largely what happened in the hour that followed.
